NCT04488978View on ClinicalTrials.gov

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

PHASE2CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

November 9, 2021

Study Completion Date

November 9, 2021

Conditions
Essential Hypertension
Interventions
DRUG

Irbesartan/Amlodipine

QID

Trial Locations (1)

03722

Yonsei University Health System, Severance Hospital, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY

NCT04488978 - Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension | Biotech Hunter | Biotech Hunter